Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ewabCduTtWCiybxnCidncVCicNybDf
| Today's Top Story |  |  | | | Health Care & Policy | | | | - Collaborative effort spawns flu vaccine in one week
Scientists at Novartis Vaccines and Diagnostics made a synthetic flu vaccine in one week -- the result of a collaboration with the HHS Biomedical Advanced Research and Development Authority and the J. Craig Venter Institute. The CDC provided researchers with parts of the genetic code for an unidentified flu virus, and the researchers used enzymes and a custom software program to synthesize an effective vaccine. The work is described in Science Translational Medicine. Genetic Engineering & Biotechnology News (5/15)       - 3 cancer drugs from AstraZeneca set to enter late-stage trials
AstraZeneca plans to advance its three cancer drug candidates into Phase III trials. Set to advance are moxetumomab pasudotox for patients with hairy cell leukemia, selumetinib for patients with KRAS-positive nonsmall-cell lung cancer, and olaparib for patients with platinum-sensitive relapsed ovarian cancer. The firm also plans to double the number of drugs in its late-stage pipeline and submit three regulatory applications by 2016. Bloomberg Businessweek (5/16) - Researchers use iPS cells to produce hematopoietic stem cells
Researchers in Japan said they were able to create hematopoietic stem cells from induced pluripotent stem cells. The method involved inducing benign tumors in mice using iPS cells and then adding catalysts to trigger the formation of blood-producing stem cells. The team hopes to develop a method for creating cells that does not rely on the use of tumors. The Mainichi (Japan) (5/15) - Developer of rare-disease drugs gets $4.6M boost
A Series A funding round has brought in $4.6 million for Callidus Biopharma, a development-stage biotech firm specializing in rare-disease drugs. The Pennsylvania-based company plans to use the proceeds mainly to speed up preclinical development of its drug candidates for lysosomal storage disorders, including Pompe and Gaucher diseases. Money also will go toward the launch of the firm's proprietary protein-expression technology. American City Business Journals/Philadelphia (5/16)  | Analyst Paper - ARC Brief: Infrastructure: the Hidden Optimization Opportunity
New technologies allow preventative and predictive maintenance coupled with EAM and analytics to be applied to infrastructure. Those responsible for maintaining facilities, fleets, and linear assets should investigate strategies for improving the effectiveness of the maintenance function. Learn more in the free report. |
| Food & Agriculture | | | | | Industrial & Environmental | | | | - Enerkem gets $1.1M boost for advanced-biofuel R&D project
The Canadian government will invest $1.1 million in a research project by Enerkem to develop new catalytic processes for turning waste into advanced biofuels, the company said. Enerkem will conduct the three-year project at its pilot-scale facility in Quebec with the help of the University of Sherbrooke. Meanwhile, construction of Enerkem's first commercial-scale facility is "progressing well" in Edmonton, with commissioning slated to begin in the summer, a spokeswoman said. BiofuelsDigest.com (5/15)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Save on energy costs through BIO's newest cost-savings program
BIO has recently aligned with APPI Energy, an energy consulting firm, to assist member companies with reducing their energy expenses. APPI Energy, the preferred energy consultant of 140 trade associations and chambers of commerce nationwide, provides solutions to reduce electricity and natural gas costs at no risk or obligation to member companies. Through this program, APPI Energy offers specialized energy cost reduction services, including the identification of reliable and competitive energy suppliers for member companies and the obtaining of competitive bids from the preferred suppliers in deregulated energy markets. Learn more.
| SmartQuote | | | |  | Divide each difficulty into as many parts as is feasible and necessary to resolve it."
--René Descartes,
French mathematician and philosopher  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, May 16, 2013
- Wednesday, May 15, 2013
- Tuesday, May 14, 2013
- Monday, May 13, 2013
- Friday, May 10, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment